ストックスクリーナーアプリを入手
10.13
1.27%
-0.13
プレマーケット:
10.20
0.07
+0.69%
前日終値:
$10.26
開ける：
$10.33
24時間の取引高:
13.07M
Relative Volume:
8.42
時価総額：
$387.71M
収益：
$127.70M
当期純損益:
$-121.25M
株価収益率:
-3.2159
EPS:
-3.15
ネットキャッシュフロー:
$-120.32M
1週間 パフォーマンス:
-2.13%
1か月 パフォーマンス:
+1.71%
6か月 パフォーマンス:
+25.68%
1年 パフォーマンス:
-35.60%
1日の値動き範囲:
$10.11
$10.47
1週間の範囲:
$10.11
$10.47
52週間の値動き範囲:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
ITOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.13 | 396.13M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-05-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-13 | 開始されました | Wells Fargo | Overweight |
| 2021-05-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | SVB Leerink | Outperform |
| 2020-08-18 | 開始されました | Wedbush | Outperform |
すべてを表示
Iteos Therapeutics Inc (ITOS) 最新ニュース
Is iTeos Therapeutics Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush - Defense World
Securities Law Risks in Biotech M&A: A Closer Look at iTeos Therapeutics' Proposed Acquisition - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - GlobeNewswire Inc.
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations - AInvest
Navigating ITOS Stock: ITeos Therapeutics Inc Journey - investchronicle.com
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - The Globe and Mail
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Concentra To Acquire ITeos - Nasdaq
The Strategic Rationale and Valuation Implications of Concentra Biosciences' Acquisition of iTeos Therapeutics - AInvest
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Quiver Quantitative
iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
iTeos Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - Informazione.it
What analysts say about iTeos Therapeutics Inc. stockOutstanding trading profits - jammulinksnews.com
What risks could impact iTeos Therapeutics Inc. stock performanceFree Stock Index Interpretation - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment - TipRanks
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market Expert Consultation - Newser
What makes iTeos Therapeutics Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab - TipRanks
iTeos Therapeutics (ITOS): An Example of Biotech Liquidations - MSN
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
(ITOS) Technical Data - news.stocktradersdaily.com
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock By Investing.com - Investing.com Nigeria
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Exchange Traded Concepts LLC Acquires 3,468 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics Holds Annual Stockholders Meeting - TipRanks
Stock Performance Spotlight: ITeos Therapeutics Inc (ITOS) Ends the Day at 10.10, Down by -0.69 - DWinneX
Learn to Evaluate (ITOS) using the Charts - news.stocktradersdaily.com
ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing - MarketScreener
Bank of America Corp DE Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) PT at $15.86 - Defense World
ITeos Therapeutics Insider Sold Shares Worth $1,592,520, According to a Recent SEC Filing - marketscreener.com
Iteos Therapeutics Inc (ITOS) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):